ClearPoint Neuro (CLPT) EBT (2011 - 2026)

ClearPoint Neuro has disclosed EBT across 15 years of filings, most recently posting -$9.5 million for Q1 2026.

• EBT for Q1 2026 came in at -$9.5 million, down 58.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.0 million (down 39.67% YoY), and the FY2025 annual result was -$25.5 million, down 34.83% from the prior year.
• EBT came in at -$9.5 million for Q1 2026 at ClearPoint Neuro, down from -$7.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$3.8 million in Q3 2022 to a low of -$9.5 million in Q1 2026.
• The 5-year median for EBT is -$5.0 million (2024), against an average of -$5.5 million.
• Across the five-year window, EBT slumped 66.03% in 2023 and soared 38.4% in 2024, its largest moves.
• ClearPoint Neuro's EBT stood at -$4.5 million in 2022, then retreated by 5.3% to -$4.7 million in 2023, then decreased by 15.13% to -$5.4 million in 2024, then slumped by 43.63% to -$7.8 million in 2025, then retreated by 22.64% to -$9.5 million in 2026.
• The last three EBT figures came in at -$9.5 million (Q1 2026), -$7.8 million (Q4 2025), and -$5.9 million (Q3 2025), per Business Quant data.